Recursion

Recursion Publishes Annual Environmental, Social and Governance Report

Retrieved on: 
Tuesday, March 26, 2024
Institutional Shareholder Services, Recursion, Culture, Entrepreneurship, Biophysical environment, Drug discovery, ESG, Patient, United Nations, AI, Biology, Social, Sustainability accounting, TCFD, Task force, ISS, UN, Pharmaceutical industry

SALT LAKE CITY, March 26, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced the release of its third annual Environmental, Social and Governance (ESG) Report .

Key Points: 
  • SALT LAKE CITY, March 26, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced the release of its third annual Environmental, Social and Governance (ESG) Report .
  • The report highlights the company’s approach, progress and goals in several important areas such as its commitment to patients, social and community impact, people and culture, environmental sustainability, and governance.
  • Efficiency – in our context – drives a more sustainable healthcare system,” said Chris Gibson, Ph.D., Co-Founder and CEO at Recursion.
  • You can learn more about Recursion’s approach to ESG and download a copy of the report at www.Recursion.com/esg .

Noetik Appoints Dr. Shafique Virani as Chief Business Officer

Retrieved on: 
Wednesday, March 27, 2024
Research, Technology, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Recursion, Neuromyelitis optica spectrum disorder, University, Drug discovery, Patient, Cancer, Medicine, Doctor of Philosophy, Bayer, Therapy, COA, Machine learning, CSO, Multimedia, Pharmaceutical industry

Noetik , an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer.

Key Points: 
  • Noetik , an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240327236059/en/
    "We are thrilled to welcome Shaf to our team as Chief Business Officer.
  • Prior to joining Noetik, Dr. Virani served as Recursion’s Chief Corporate Development Officer, as well as the interim Chief Medical Officer as part of his tenure.
  • As Chief Business Officer, Dr. Virani will accelerate Noetik’s mission through both business development and portfolio strategy by identifying and facilitating strategically impactful transactions.

Recursion Announces Plans to Open New Office in London

Retrieved on: 
Monday, March 11, 2024
Acquisition, DeepMind, Merck, BREEAM, Chemistry, Research, Investment, Drug discovery, Carbon, Lead, Walking, St Pancras railway station, Ecosystem, University of Oxford, San Francisco Bay Area, Heart, Biology, Artificial intelligence, Recursion, Management

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood.

Key Points: 
  • LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood.
  • "London stood out as an ideal location given its brilliant and interdisciplinary talent across the fields of technology, biology and chemistry.
  • Recursion’s new London office will serve as an extension of both Recursion and Valence Labs’ teams.
  • To launch recruiting efforts for the new site, Recursion has opened multiple new roles across technology and biology functions with immediate plans to hire the first 20 people to be based out of the new London office.

Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community

Retrieved on: 
Friday, March 1, 2024
Rare disease, RUN, Intelligence, Drug discovery, Nature, Hope, Entrepreneurship, ARUP Laboratories, University, Organization, Patient, Disease, Diagnosis, Biology, RDAC, RARE, Recursion, Laboratory, Partnership, Pharmaceutical industry

An estimated one in 10 people in the United States have a rare disease.

Key Points: 
  • An estimated one in 10 people in the United States have a rare disease.
  • The event recognized advocates who have been instrumental in building Utah’s rare disease community and have dedicated themselves to support this important work.
  • “There is an urgency for diagnoses, treatment and cures for the rare disease community,” said Gina Zanik, co-founder and executive director of Rare and Undiagnosed Network and Vice Chair of the Utah Rare Disease Advisory Council.
  • Rare disease patients came together at Recursion with the RARE and Undiagnosed Network (RUN), RARE-X , BioHive , ARUP Laboratories , BioUtah , the University of Utah and the Rare Disease Advisory Council (RDAC) for the Rare Disease Day event.

Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research

Retrieved on: 
Thursday, February 22, 2024
General Health, Health, Science, Pharmaceutical, Research, Bachelor of Science, Woman, Doctor of Philosophy, Seek, STEM, WITS, Inflammation, Drug discovery, Global health, University College Cork, Patient, Fibrosis, Knowledge, Microbiology, Recursion, Pharmaceutical industry

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development.

Key Points: 
  • Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development.
  • With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony brings extensive knowledge and expertise to Seek Labs where she will spearhead the pharmaceutical research division, leading strategic initiatives to advance Seek Labs’ innovation in novel gene therapies.
  • "We are delighted to welcome Alison O’Mahony to Seek Labs as our new Vice President of Pharmaceutical Development," said Jared Bauer, CEO.
  • She also serves on professional boards including Talent Ready Utah, Breakthrough Cancer Research, and the Inflammation Research Association.

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

Retrieved on: 
Thursday, January 4, 2024
Science, Drug discovery, Bayer, Research, Disease, Chemistry, Mortality, Recursion, Patient, Pharmaceutical industry

The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction.

Key Points: 
  • The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction.
  • Leveraging the power of Recursion’s Maps of Biology and Chemistry revealed a relationship between small molecule hits and a novel target that could impact fibrotic diseases.
  • Fibrotic diseases are a significant cause of morbidity and mortality worldwide with high unmet need for patients.
  • One of the biggest challenges in the treatment of fibrotic diseases is the underlying complex biology and the associated difficulty in discovering disease-modifying drug targets.

Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8

Retrieved on: 
Wednesday, January 3, 2024
Biology, Recursion, Conference, Drug discovery

SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Chris Gibson, Ph.D., Co-founder and CEO, will help kick off the 42nd Annual J.P. Morgan Healthcare Conference with a presentation on Monday, January 8, 2024 at 7:30 am PT.

Key Points: 
  • SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Chris Gibson, Ph.D., Co-founder and CEO, will help kick off the 42nd Annual J.P. Morgan Healthcare Conference with a presentation on Monday, January 8, 2024 at 7:30 am PT.
  • A live audio webcast of Chris’s presentation will be available through the Investor Relations section of the Recursion website.

Bayer and Recursion focus research collaboration on Oncology

Retrieved on: 
Thursday, November 9, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Recursion, Artificial intelligence, Chemistry, Business development, Executive Committee, Data, Patient, Multimedia, USD, Therapy, Drug discovery, Cancer, S-1 Executive Committee, Bias, Biology, Pharmaceutical industry, Medical device, Bayer

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology.

Key Points: 
  • Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology.
  • This strategic shift will enable Bayer to utilize Recursion’s capabilities to initiate and advance the identification of novel therapeutic targets for challenging oncology indications with high unmet need.
  • “Every cancer is different and requires an individual approach,” said Dominik Ruettinger, M.D., Ph.D., Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG.
  • Leaps by Bayer, the impact investment arm of Bayer AG, led Recursion’s Series D financing in 2020 with an investment of USD 50 million.

Bayer and Recursion Focus Research Collaboration on Oncology

Retrieved on: 
Thursday, November 9, 2023
Bayer, Therapy, Business development, Data, Research, Artificial intelligence, Biology, Drug discovery, Recursion, USD, Cancer, Chemistry, Patient, Bias, Pharmaceutical industry

Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology.

Key Points: 
  • Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology.
  • This strategic shift will enable Bayer to utilize Recursion’s capabilities to initiate and advance the identification of novel therapeutic targets for challenging oncology indications with high unmet need.
  • "Every cancer is different and requires an individual approach," said Dominik Ruettinger, M.D., Ph.D., Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG.
  • Leaps by Bayer, the impact investment arm of Bayer AG, led Recursion’s Series D financing in 2020 with an investment of USD 50 million.

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

Retrieved on: 
Thursday, November 9, 2023
Therapy, RNA, Genetics, SALT, NVIDIA, Deep learning super sampling, Medicine, Biology, Drug discovery, Recursion, Benchmarking, Health, AI, Chemistry, Patient, Biotechnology, DNA, Pharmaceutical industry, Tempus, Bayer, Medication

“Today, we are thrilled to share three major initiatives that support this belief and our mission to bring better medicines to patients at speed and scale.

Key Points: 
  • “Today, we are thrilled to share three major initiatives that support this belief and our mission to bring better medicines to patients at speed and scale.
  • By combining the forward genetics approach of Tempus with the reverse genetics approach at Recursion, the company believes it has an opportunity to improve the speed, precision and scale of therapeutic development in oncology.
  • “We share Recursion’s commitment to a data-first approach to precision medicine,” said Eric Lefkofsky, Founder and CEO of Tempus.
  • This decision allows Bayer to leverage Recursion’s state-of-the-art capabilities to identify novel targets and chemistry applicable to oncology indications.